Insider Selling: Mesa Laboratories (NASDAQ:MLAB) SVP Sells $225,182.00 in Stock

Posted by Geri Gentry on Jun 26th, 2026

Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Free Report) SVP Brian David Archbold sold 2,516 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $225,182.00. Following the completion of the transaction, the senior vice president directly owned 6,377 shares of the company’s stock, valued at $570,741.50. The trade was a 28.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Brian David Archbold also recently made the following trade(s):

On Tuesday, June 16th, Brian David Archbold sold 1,151 shares of Mesa Laboratories stock. The stock was sold at an average price of $101.27, for a total transaction of $116,561.77.

Mesa Laboratories Trading Up 3.9%

Shares of Mesa Laboratories stock opened at $98.15 on Friday. The firm’s 50 day simple moving average is $101.79 and its two-hundred day simple moving average is $91.35. The firm has a market capitalization of $542.28 million, a price-to-earnings ratio of 81.79 and a beta of 0.94. Mesa Laboratories, Inc. has a 12-month low of $55.45 and a 12-month high of $113.99. The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78.

Mesa Laboratories (NASDAQ:MLAB – Get Free Report) last announced its quarterly earnings data on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%. The company had revenue of $63.72 million for the quarter, compared to analysts’ expectations of $65.21 million. During the same period last year, the firm earned ($1.31) earnings per share.

Mesa Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 15th. Shareholders of record on Friday, May 29th were paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, May 29th. Mesa Laboratories’s payout ratio is presently 53.33%.

Hedge Funds Weigh In On Mesa Laboratories

Institutional investors have recently modified their holdings of the stock. Boston Partners lifted its holdings in shares of Mesa Laboratories by 86.6% in the 4th quarter. Boston Partners now owns 213,376 shares of the medical instruments supplier’s stock valued at $16,752,000 after buying an additional 99,019 shares during the period. Simcoe Capital Management LLC purchased a new stake in shares of Mesa Laboratories in the third quarter worth about $12,794,000. Royce & Associates LP grew its holdings in Mesa Laboratories by 3.2% during the fourth quarter. Royce & Associates LP now owns 153,352 shares of the medical instruments supplier’s stock worth $12,038,000 after acquiring an additional 4,794 shares during the period. Kennedy Capital Management LLC grew its holdings in Mesa Laboratories by 19.0% during the fourth quarter. Kennedy Capital Management LLC now owns 144,606 shares of the medical instruments supplier’s stock worth $11,352,000 after acquiring an additional 23,060 shares during the period. Finally, Diamond Hill Capital Management Inc. raised its position in Mesa Laboratories by 15.1% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 141,973 shares of the medical instruments supplier’s stock valued at $11,145,000 after acquiring an additional 18,592 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Mesa Laboratories currently has an average rating of “Reduce” and a consensus price target of $94.00.

View Our Latest Research Report on Mesa Laboratories

About Mesa Laboratories

(Get Free Report)

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.